IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Insider Jason Throne Sells 1,000 Shares of Stock

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) insider Jason Throne sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $30.00, for a total transaction of $30,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jason Throne also recently made the following trade(s):

• On Friday, September 1st, Jason Throne sold 2,100 shares of IDEAYA Biosciences stock. The stock was sold at an average price of $30.03, for a total transaction of $63,063.00.
• On Tuesday, September 5th, Jason Throne sold 1,737 shares of IDEAYA Biosciences stock. The stock was sold at an average price of $30.03, for a total transaction of $52,162.11.
• On Wednesday, August 9th, Jason Throne sold 5,000 shares of IDEAYA Biosciences stock. The stock was sold at an average price of $25.09, for a total transaction of $125,450.00.
• On Monday, July 10th, Jason Throne sold 9,485 shares of IDEAYA Biosciences stock. The stock was sold at an average price of $23.00, for a total transaction of $218,155.00.

IDEAYA Biosciences Price Performance

IDYA opened at $29.49 on Friday. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -20.34 and a beta of 0.75. The company’s 50 day simple moving average is $24.95 and its two-hundred day simple moving average is $21.26. IDEAYA Biosciences, Inc. has a 1-year low of $10.60 and a 1-year high of $30.25.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.05. IDEAYA Biosciences had a negative net margin of 164.25% and a negative return on equity of 19.09%. The firm had revenue of $3.50 million for the quarter, compared to analysts’ expectations of $4.89 million. The company’s revenue was down 55.7% on a year-over-year basis. On average, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -2.01 earnings per share for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of IDYA. BVF Inc. IL increased its holdings in IDEAYA Biosciences by 131.5% in the 2nd quarter. BVF Inc. IL now owns 5,683,489 shares of the company’s stock valued at $133,562,000 after purchasing an additional 3,228,400 shares during the last quarter. BlackRock Inc. boosted its position in shares of IDEAYA Biosciences by 22.7% during the second quarter. BlackRock Inc. now owns 4,355,696 shares of the company’s stock worth $102,359,000 after buying an additional 806,603 shares during the period. Avidity Partners Management LP grew its stake in shares of IDEAYA Biosciences by 2.9% in the fourth quarter. Avidity Partners Management LP now owns 3,824,800 shares of the company’s stock valued at $69,497,000 after buying an additional 109,400 shares in the last quarter. State Street Corp raised its holdings in shares of IDEAYA Biosciences by 1.1% in the 2nd quarter. State Street Corp now owns 2,138,503 shares of the company’s stock valued at $50,255,000 after buying an additional 24,186 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of IDEAYA Biosciences by 9.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,924,600 shares of the company’s stock valued at $28,715,000 after buying an additional 171,759 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IDYA. Oppenheimer lifted their target price on shares of IDEAYA Biosciences from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Friday, August 11th. SVB Securities initiated coverage on shares of IDEAYA Biosciences in a research note on Tuesday, August 8th. They set an “outperform” rating and a $33.00 price objective for the company. Leerink Partnrs restated an “outperform” rating on shares of IDEAYA Biosciences in a research note on Tuesday, August 8th. Wedbush lifted their price objective on shares of IDEAYA Biosciences from $40.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of IDEAYA Biosciences from $28.00 to $32.00 and gave the company an “overweight” rating in a research note on Thursday, August 17th. Fourteen analysts have rated the stock with a buy rating, According to MarketBeat, IDEAYA Biosciences has a consensus rating of “Buy” and an average target price of $32.08.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.